Study: Directly observed HIV therapy for children is promising

May 31, 2007



PROVIDENCE, R.I. [Brown University] -- Directly observed antiretroviral therapy is a promising strategy to ensure that HIV-infected children in developing countries take life-saving medications, new research from The Warren Alpert Medical School of Brown University shows.

The study was conducted in collaboration with Maryknoll, the international Catholic charity that runs a program for AIDS orphans in Phnom Penh, Cambodia's capital city. The study is the first to test the benefits of directly observed treatment in children living in developing countries. Findings are published in the June issue of the American Journal of Public Health.

"Results of this study tell us that directly observed treatment for children with HIV is an important strategy to consider in resource-limited settings" said David Pugatch, M.D., director of the pediatric and adolescent HIV program at Hasbro Children's Hospital and an assistant professor of pediatrics at The Alpert Medical School.

"With the cost of AIDS drugs dropping, antiretroviral treatments are increasingly becoming available in Asia, Africa and Latin America," Pugatch said, "yet there is little evidence of what is the best way to deliver these drugs to children living in these countries. We found that directly observed therapy is an effective and economical way to go."

Without antiretroviral treatment, half of all HIV-infected children die by age 2. With therapy, however, many children survive to adulthood. That's why the World Health Organization is calling for worldwide universal access to antiretroviral therapy by 2010.

But what's the best way to deliver these drugs to children in developing countries, places with often limited access to basic tests and trained professionals" Pugatch and his Brown colleagues, who have helped combat AIDS in Cambodia for years, decided to find out.

They evaluated the outcomes of HIV-infected children receiving directly observed therapy, a method that calls for health care workers to either watch patients take every drug dose or deliver those doses themselves. This method, widely used to combat tuberculosis, is aimed at ensuring that people take their medications. That adherence will keep patients healthy and reduce the likelihood of drug resistance.

Researchers evaluated HIV-infected children living in orphanages or with extended family in Phnom Penh. Researchers assessed 117 late-stage HIV-infected children ages 1 to 13.

Because treatment started so late, 22 children died of AIDS within the first six months. The remaining 95 children were treated for at least six months or as many as 18 months. Trained childcare workers administered the generic drugs, in liquid or pill form, twice daily.

The results: The number of immunity-boosting T helper cells in the blood of children more than tripled. Children gained significant amounts of weight. Drug toxicities were uncommon and easily managed. And the price was right: Staff costs for the program were about $5 per child per month, or 15 percent more than the price of the medications. Calculated another way, it cost $400 per child per year to buy the drugs and another $60 to pay the professionals who administered them.

"For just a little extra money, we could be sure that children had 100 percent adherence to their medications," Pugatch said. "We know that a high degree of adherence reduces the chances of drug resistance - which can lead to treatment failure and the need to put kids on more expensive, second-line therapies."

The next steps researchers must take, Pugatch said, are to conduct a randomized, controlled trial to compare directly observed therapy with standard care as well as to conduct a rigorous cost-benefit analysis. "We need to know what works in treating children in resource-poor settings so we know where to put limited HIV treatment dollars," he said.
-end-
Patricia Myung, M.D., a former Brown medical student and current resident at the University of California-Irvine, is lead author of the article. Brown medical student Mark Brady was part of the research team, along with Mark Lurie, assistant professor of community health, and Joseph Harwell, M.D., assistant professor of medicine and pediatrics and attending physician at The Miriam Hospital. Former Maryknoll program directors Phok Many and John Tucker also conducted the research.

The International Health Institute at Brown University and the Brown-Tufts Fogarty AIDS International Training and Research Program funded the work.

Editors: Brown University has a fiber link television studio available for domestic and international live and taped interviews and maintains an ISDN line for radio interviews. For more information, call the Office of Media Relations at (401) 863-2476.

Brown University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.